Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | PRMT5 | O14744 | 9/20 | 0.44 |
| ▸ | WDR77 | Q9BQA1 | 6/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.39 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5456187 | 0.88 | DRD2 (0.47) | DRD2HTR2APRMT5WDR77MEN1 | |
| SCHEMBL5447880 | 0.84 | DRD2 (0.48) | DRD2HTR2APRMT5WDR77MEN1 | |
| SCHEMBL5453861 | 0.83 | DRD2 (0.48) | DRD2HTR2APRMT5WDR77MEN1 | |
| SCHEMBL5450109 | 0.81 | MEN1 (0.52) | DRD2HTR2APRMT5WDR77MEN1 | |
| SCHEMBL5456100 | 0.78 | MEN1 (0.46) | DRD2HTR2AMEN1KMT2AL3MBTL1 | |
| SCHEMBL5451891 | 0.77 | MTNR1A (0.48) | DRD2HTR2APRMT5WDR77MEN1 | |
| SCHEMBL5454530 | 0.75 | DRD2 (0.58) | DRD2HTR2APRMT5WDR77MEN1 | |
| SCHEMBL5803509 | 0.75 | S1PR5 (0.52) | DRD2HTR2APRMT5WDR77MEN1 | |
| SCHEMBL5453570 | 0.74 | DRD2 (0.41) | DRD2HTR2AMEN1KMT2AL3MBTL1 | |
| SCHEMBL5451842 | 0.74 | MTNR1A (0.44) | DRD2HTR2AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | IONIX PHARMACEUTICALS LIMITED (GB) | 2007-02-22 | — | — | US | disclosed |
| EP-1660454-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | Vernalis (R&D) Limited (GB) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005005392-A1 | AZACYCLIC COMPOUNDS AS INHIBITORS OF SENSORY NEURONE SPECIFIC CHANNELS | IONIX PHARMACEUTICALS LIMITED (GB) | 2005-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070043024-A1 | Azacyclic compounds as inhibitors of sensory neurone specific channels | SCN1B, SCN1A, SCN10A | DRD2 1065/4885HTR2A 955/4885PRMT5 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.